
Look Forward – Spring 2022 – Issue 176
This edition of Look Forward is packed full of details of our plans for 2022. There is so much going on and being able to get together in person is a big part of that.
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.
This edition of Look Forward is packed full of details of our plans for 2022. There is so much going on and being able to get together in person is a big part of that.
Alex Pitts from British Blind Sport talks about the benefits of sport and physical activity and the BBS Have a Go Days and Active at Home programme.
Prof Dominic Ffytche will provide an explanation of what Charles Bonnet Syndrome is, the science behind it, and share some potential coping strategies for people who experience visual hallucinations.
A general overview of the clinical trials process and practicalities, including issues to consider if you are given the opportunity to take part.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Inflammation and retinal degeneration in retinitis pigmentosa: Can lessons learned in the lab help us identify treatments in the clinic?
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Elena Piotter, a PhD student working in Robert MacLaren’s group in the Nuffield Laboratory of Ophthalmology at the University of Oxford, is currently researching DNA and RNA base editing tools aiming to correct pathogenic mutations in ABCA4.